Literature DB >> 25344840

Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity.

Sailu Sarvagalla1, Vivek Kumar Singh, Yi-Yu Ke, Hui-Yi Shiao, Wen-Hsing Lin, Hsing-Pang Hsieh, John T A Hsu, Mohane Selvaraj Coumar.   

Abstract

Furanopyrimidine 1 (IC50 = 273 nM, LE = 0.36, LELP = 10.28) was recently identified by high-throughput screening (HTS) of an in-house library (125,000 compounds) as an Aurora kinase inhibitor. Structure-based hit optimization resulted in lead molecules with in vivo efficacy in a mouse tumour xenograft model, but no oral bioavailability. This is attributed to "molecular obesity", a common problem during hit to lead evolution during which degradation of important molecular properties such as molecular weight (MW) and lipophilicity occurs. This could be effectively tackled by the right choice of hit compounds for optimization. In this regard, ligand efficiency (LE) and ligand efficiency dependent lipophilicity (LELP) indices are more often used to choose fragment-like hits for optimization. To identify hits with appropriate LE, we used a MW cut-off <250, and pyrazole structure to filter HTS library. Next, structure-based virtual screening using software (Libdock and Glide) in the Aurora A crystal structure (PDB ID: 3E5A) was carried out, and the top scoring 18 compounds tested for Aurora A enzyme inhibition. This resulted in the identification of a novel tetrahydro-pyrazolo-isoquinoline hit 7 (IC50 = 852 nM, LE = 0.44, LELP = 8.36) with fragment-like properties suitable for further hit optimization. Moreover, hit 7 was found to be selective for Aurora A (Aurora B IC50 = 35,150 nM) and the possible reasons for selectivity investigated by docking two tautomeric forms (2H- and 3H-pyrazole) of 7 in Auroras A and B (PDB ID: 4AF3) crystal structures. This docking study shows that the major 3H-pyrazole tautomer of 7 binds in Aurora A stronger than in Aurora B.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25344840     DOI: 10.1007/s10822-014-9807-2

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  28 in total

Review 1.  Protein kinase inhibitors: insights into drug design from structure.

Authors:  Martin E M Noble; Jane A Endicott; Louise N Johnson
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

2.  An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs.

Authors:  Emanuele Perola
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

3.  Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.

Authors:  Hui-Yi Shiao; Mohane Selvaraj Coumar; Chun-Wei Chang; Yi-Yu Ke; Ya-Hui Chi; Chang-Ying Chu; Hsu-Yi Sun; Chun-Hwa Chen; Wen-Hsing Lin; Ka-Shu Fung; Po-Chu Kuo; Chin-Ting Huang; Kai-Yen Chang; Cheng-Tai Lu; John T A Hsu; Chiung-Tong Chen; Weir-Torn Jiaang; Yu-Sheng Chao; Hsing-Pang Hsieh
Journal:  J Med Chem       Date:  2013-06-28       Impact factor: 7.446

Review 4.  Roles of Aurora kinases in mitosis and tumorigenesis.

Authors:  Jingyan Fu; Minglei Bian; Qing Jiang; Chuanmao Zhang
Journal:  Mol Cancer Res       Date:  2007-01       Impact factor: 5.852

5.  Ligand efficiency based approach for efficient virtual screening of compound libraries.

Authors:  Yi-Yu Ke; Mohane Selvaraj Coumar; Hui-Yi Shiao; Wen-Chieh Wang; Chieh-Wen Chen; Jen-Shin Song; Chun-Hwa Chen; Wen-Hsing Lin; Szu-Huei Wu; John T A Hsu; Chung-Ming Chang; Hsing-Pang Hsieh
Journal:  Eur J Med Chem       Date:  2014-06-14       Impact factor: 6.514

6.  Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.

Authors:  Mohane Selvaraj Coumar; Chang-Ying Chu; Cheng-Wei Lin; Hui-Yi Shiao; Yun-Lung Ho; Randheer Reddy; Wen-Hsing Lin; Chun-Hwa Chen; Yi-Hui Peng; Jiun-Shyang Leou; Tzu-Wen Lien; Chin-Ting Huang; Ming-Yu Fang; Szu-Huei Wu; Jian-Sung Wu; Santhosh Kumar Chittimalla; Jen-Shin Song; John T-A Hsu; Su-Ying Wu; Chun-Chen Liao; Yu-Sheng Chao; Hsing-Pang Hsieh
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

Review 7.  Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).

Authors:  Chun Hei Antonio Cheung; Mohane Selvaraj Coumar; Jang-Yang Chang; Hsing-Pang Hsieh
Journal:  Expert Opin Ther Pat       Date:  2011-06       Impact factor: 6.674

Review 8.  Pyrazole scaffold: a remarkable tool in the development of anticancer agents.

Authors:  Harish Kumar; Deepika Saini; Sandeep Jain; Neelam Jain
Journal:  Eur J Med Chem       Date:  2013-10-09       Impact factor: 6.514

Review 9.  Aurora kinase inhibitors: progress towards the clinic.

Authors:  Madhu Kollareddy; Daniella Zheleva; Petr Dzubak; Pathik Subhashchandra Brahmkshatriya; Martin Lepsik; Marian Hajduch
Journal:  Invest New Drugs       Date:  2012-02-18       Impact factor: 3.850

10.  Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2.

Authors:  Baoguang Zhao; Angela Smallwood; Jingsong Yang; Kristin Koretke; Kelvin Nurse; Amy Calamari; Robert B Kirkpatrick; Zhihong Lai
Journal:  Protein Sci       Date:  2008-07-28       Impact factor: 6.725

View more
  20 in total

1.  Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.

Authors:  Vivek Kumar Singh; Mohane Selvaraj Coumar
Journal:  J Mol Model       Date:  2017-07-01       Impact factor: 1.810

2.  Homology modeling, substrate docking, and molecular simulation studies of mycobacteriophage Che12 lysin A.

Authors:  Shainaba A Saadhali; Sameer Hassan; Luke Elizabeth Hanna; Uma Devi Ranganathan; Vanaja Kumar
Journal:  J Mol Model       Date:  2016-07-13       Impact factor: 1.810

3.  Repositioning antispasmodic drug Papaverine for the treatment of chronic myeloid leukemia.

Authors:  Phani Krishna Parcha; Sailu Sarvagalla; Cheemala Ashok; S J Sudharshan; Madhu Dyavaiah; Mohane Selvaraj Coumar; Baskaran Rajasekaran
Journal:  Pharmacol Rep       Date:  2021-01-03       Impact factor: 3.024

4.  Effective natural inhibitors targeting IGF-1R by computational study.

Authors:  Xinyu Wang; Pengcheng Zhou; Liangxin Lin; Bo Wu; Zhaoyu Fu; Xing Huang; Dong Zhu
Journal:  Aging (Albany NY)       Date:  2022-06-09       Impact factor: 5.955

5.  Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.

Authors:  Yi-Yu Ke; Vivek Kumar Singh; Mohane Selvaraj Coumar; Yung Chang Hsu; Wen-Chieh Wang; Jen-Shin Song; Chun-Hwa Chen; Wen-Hsing Lin; Szu-Huei Wu; John T A Hsu; Chuan Shih; Hsing-Pang Hsieh
Journal:  Sci Rep       Date:  2015-06-29       Impact factor: 4.379

6.  Molecular Shape Analysis-Guided Virtual Screening Platform for Adenosine Kinase Inhibitors.

Authors:  Savita Bhutoria; Ballari Das; Nanda Ghoshal
Journal:  Bioinform Biol Insights       Date:  2016-07-18

7.  Computational study of novel natural inhibitors targeting aminopeptidase N(CD13).

Authors:  Junliang Ge; Zhongfeng Wang; Ye Cheng; Junan Ren; Bo Wu; Weihang Li; Xinhui Wang; Xing Su; Ziling Liu
Journal:  Aging (Albany NY)       Date:  2020-05-09       Impact factor: 5.682

8.  Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases.

Authors:  Xiaoli Zhou; Shanshan Yu; Jing Su; Liankun Sun
Journal:  Int J Mol Sci       Date:  2016-03-04       Impact factor: 5.923

9.  GEPSI: A Gene Expression Profile Similarity-Based Identification Method of Bioactive Components in Traditional Chinese Medicine Formula.

Authors:  Baixia Zhang; Shuaibing He; Chenyang Lv; Yanling Zhang; Yun Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-06       Impact factor: 2.629

10.  Computational study on novel natural inhibitors targeting BCL2.

Authors:  Xiaye Lv; Yuting Jiang; Xinhui Wang; HaoQun Xie; Gaojing Dou; Jing Wang; Wenzhuo Yang; Hongyu Wang; Zijian Li; Xiangheng Zhang; Zhenghe Chen
Journal:  Med Oncol       Date:  2021-07-14       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.